Aspire Biopharma Executes Securities Purchase Agreement

On February 20, 2025, Aspire Biopharma, Inc., based in New York, announced the signing of a Securities Purchase Agreement. This agreement involves issuing a senior secured convertible debenture, expected to close by February 20, 2025. Aspire will gain $3 million in gross proceeds from the transaction, aimed at supporting its working capital and operating expenses.

CEO Kraig Higginson stated that the debenture is structured to avoid common DESPAC transaction issues. It also limits investors from selling more than 15% of the daily volume, thereby strengthening Aspire's capital structure and enhancing liquidity. Aspire aims to continue developing FDA-approved drug formulations and nutraceuticals.

Dawson James Securities, Inc. and RBW Capital Partners LLC are the exclusive placement agents, with legal counsel provided by ArentFox Schiff LLP and Sichenzia Ross Ference Carmel LLP.